About: Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study
Creator	Li, Ping Roy-Ghanta, Sumita Vaughn, David Van Der Most, Robbert
Source	PMC
abstract	Background. Prior receipt of a trivalent seasonal influenza vaccine (TIV) can affect hemagglutination inhibition (HI) antibody responses to pandemic influenza vaccines. We investigated the effect of TIV priming on humoral responses to AS03-adjuvanted and nonadjuvanted A(H1N1)pdm09 vaccines, the role of AS03 on cell-mediated immune (CMI) responses, and vaccine safety. Methods. Healthy adults (aged 19–40 years) were randomized 1:1:1:1 to receive TIV or saline followed 4 months later by 2 doses, 3 weeks apart, of adjuvanted or nonadjuvanted A(H1N1)pdm09 vaccine and followed up to study end (day 507). Pre- and postvaccination responses of HI and neutralizing antibody, CD4(+)/CD8(+) T cells, memory B cells, and plasmablasts were assessed. Results. Ninety-nine of the 133 participants enrolled completed the study. No vaccine-related serious adverse events were recorded. In TIV-primed participants, A(H1N1)pdm09-specific antibody and CD4(+) T-cell and memory B-cell responses to the pandemic vaccine tended to be diminished. Vaccine adjuvantation led to increased responses of vaccine-homologous and -heterologous HI and neutralizing antibodies and CD4(+) T cells, homologous memory B cells, and plasmablasts. Conclusions. In healthy adults, prior TIV administration decreased humoral and CMI responses to A(H1N1)pdm09 vaccine. Adjuvantation of A(H1N1)pdm09 antigen helped to overcome immune interference between the influenza vaccines. No safety concerns were observed. Registration. Clinical Trials.gov identifier NCT00707967.
has issue date	2014-11-01(xsd:dateTime)
bibo:doi	10.1093/infdis/jiu284
bibo:pmid	24864125
has license	cc-by-nc-nd
sha1sum (hex)	23ff47c5771980c2d6eed5db36d719336a2368f8
schema:url	https://doi.org/10.1093/infdis/jiu284
resource representing a document's title	Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study
has PubMed Central identifier	PMC4195439
has PubMed identifier	24864125
schema:publication	J Infect Dis
resource representing a document's body	covid:23ff47c5771980c2d6eed5db36d719336a2368f8#body_text
is schema:about of	named entity 'vaccines' named entity 'Prior' named entity 'vaccines' named entity 'Study' named entity 'Vaccine' named entity 'humoral responses' named entity 'TIV' named entity 'antibody' named entity 'Influenza Vaccines' named entity 'vaccination' named entity 'vaccine' named entity 'adverse events' named entity 'Pandemrix' named entity 'California' named entity 'A(H1N1)pdm09' named entity 'TIV' named entity 'joint pain' named entity 'NAb' named entity 'CD20' named entity 'reactogenicity' named entity 'CD4 +' named entity 'influenza vaccine' named entity 'B-cell' named entity 'TIV' named entity 'uterine leiomyoma' named entity 'immunogenicity' named entity 'T-cell' named entity 'adjuvanted' named entity 'titer' named entity 'CHMP' named entity 'vaccination' named entity 'adjuvanted' named entity 'TIV' named entity 'AEs' named entity 'seronegative' named entity 'TIV' named entity 'vaccination' named entity 'antigen' named entity 'antibody' named entity 'CD4 +' named entity 'hemagglutination inhibition' named entity 'Descriptive analyses' named entity 'antigens' named entity 'headache' named entity 'hemagglutination inhibition' named entity 'placebo' named entity 'B-cell' named entity 'humoral responses' named entity 'A(H1N1)pdm09' named entity 'A(H1N1)pdm09' named entity 'memory B cells' named entity 'titer' named entity 'T-cell' named entity 'upper respiratory tract infections' named entity 'adjuvanted' named entity 'T-cell' named entity 'Committee for Medicinal Products for Human Use' named entity 'CBER' named entity 'adjuvanted' named entity 'mice' named entity 'adjuvant' named entity 'MF59' named entity 'GMFRs' named entity 'NAb' named entity 'plasmablasts' named entity 'Adjuvant' named entity 'European Medicines Agency' named entity 'CD4 +' named entity 'United States' named entity 'vaccine' named entity 'titer' named entity 'H5N1' named entity 'adjuvant' named entity 'CD38' named entity 'diabetes mellitus' named entity 'vaccination' named entity 'memory B cells' named entity 'AEs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software